Peak Pharmaceuticals Launches Six New Canna-Pet Advanced Formula Products

DENVER, CO--(Marketwired - September 02, 2015) - Peak Pharmaceuticals, Inc. (OTCQB: PKPH) ("Peak Pharma" or the "Company"), a leading innovator of non-prescription hemp based cannabinoid products, is pleased to advise of exciting progress with its Canna-Pet® product lineup.

The company has launched several new products on its website which include both capsules and biscuit treats made with a new Advanced Formula of hemp cannabinoids, including CBD. The capsule products now include Canna-Pet® Advanced120 capsules, designed for medium to large dogs, as well as Advanced60 capsules for smaller animals. In addition, the Advanced Formula family offers reformulated Canna-Biscuits for Dogs in three popular flavors: Turkey Dinner, Peanut, Banana & Apple ("PB&A") and the popular Maple Bacon biscuits, which also come in a MaxCBD formulation for pet owners looking to maximize the CBD servings.

As part of the Company's overall growth strategy, management opted to streamline its product lines at the same time as partnering with a certified (cGMP) supplement manufacturer. This ensures scalability to accommodate future growth, an increased level of product quality and packaging, and access to in-house fulfillment services. Together, the changes are predicted to reduce manufacturing costs, support rapid growth while streamlining order fulfillment, and shorten shipping timelines. All of which leads to an improved experience for the company's growing customer base who can enjoy consistent, laboratory tested, quality products for their pets.

Company CEO Dr. Soren Mogelsvang notes, "This is an exciting time for us, and we are delighted to celebrate Canna-Pet's two year anniversary with the launch of our second generation of hemp products for pets. As one of the leading innovators in this space, we turned to our customers and academic collaborators for feedback to improve on the industry's first hemp supplement, Canna-Pet®. Our products are distributed to a passionate audience of consumers, veterinarians and retailers across the nation, and we try to be a leader in our young industry by providing safe, quality products, marketed responsibly to comply with our industry's regulatory agencies. To our knowledge, we are the only company in the CBD space to use a certified manufacturing facility, third party quality testing and focus on delivering safe products which contain the entire spectrum of beneficial hemp phytochemicals, not just CBD. This philosophy shows in our customer satisfaction and in the exceptional number of repeat customers. Always focused on bringing our products to new customers, we recently expanded from social media and print ads to advertising on Pandora Radio. This is an exciting first for us. We invite pet owners to give our products a try, to learn what hemp supplements can do as part of their pet's diets, and why Canna-Pet's® long-term experience and dedication to innovation set us apart in the CBD space."

About Canna-Pet® Products for Pet Health
Canna-Pet® offers hemp supplements and treats for pets, which are readily available online and at veterinary clinics. Canna-Pet® is the culmination of years of research and development to provide the benefits of hemp-based CBD and cannabinoids without the "high" typically associated with psychoactive cannabis products such as "medical marijuana." The company uses non-GMO hemp and all products are proudly manufactured in the USA. Canna-Pet products differ from its competitors by providing as many of the hemp cannabinoids and terpenes as possible, not just CBD. Canna-Pet® is a trademarked, leading producer of safe, hemp-based, cannabidiol (CBD) containing products, which are available online at: www.canna-pet.com. Follow us on Facebook and Twitter.

About Peak Pharmaceuticals, Inc. (OTCQB: PKPH)
Peak Pharmaceuticals, Inc. specializes in the development, manufacturing, sales and marketing of pharmaceutical-grade, hemp-based supplement products for the human and animal health markets. The company holds an exclusive commercial license agreement for the manufacture and sales of Canna-Pet® products and aims to become a global leader in the hemp supplement industry. For more information visit www.peakpharma.com and follow us on Facebook, Twitter and LinkedIn.

Additional details of Peak Pharmaceuticals business, finances, appointments, risks and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at www.sec.gov. For more information please visit www.peakpharma.com.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the availability of additional funding; the early-stage nature of the industry sector; regulatory changes affecting the sale, transport or consumption of Cannabidiol or hemp based products by humans or animals; commercial impacts to the Company's business, related agreements, product development, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. The Company does not undertake to update these forward-looking statements. FDA Disclosure: The statements in this news release have not been evaluated by the U.S. Food and Drug Administration (USFDA). The products mentioned herein are not intended for human consumption, or to diagnose, treat, cure, or prevent any disease. Information contained or made available through the Canna-Pet® website or affiliate sites is not intended to constitute or substitute for legal or veterinary advice.